RC
Ra Capital Management, L.P.
13F filer · CIK 0001346824Reported Aug 14, 2026
Net buyer this quarter
13F portfolio value$11.5BU.S. long equity reported on 13F
Positions8416 new · 17 closed
Net flow last quarter+$678MBuys minus sells
Top 10 positions weight60.4%Concentration
Holdings
13F · last 4 quarters freeScroll for earlier quarters
| Company | Value | % of portfolio | % of company | POSITION CHANGE qoq % | First reported |
|---|---|---|---|---|---|
| Q2 2026Reported Aug 14, 202684 positions | |||||
| $2.74B | 23.83% | 16.59% | Not reported | Q1 2015 | |
| $792M | 6.88% | 23.73% | New | Q2 2026 | |
| $740M | 6.43% | 9.69% | Not reported | Q2 2018 | |
| $667M | 5.80% | 7.93% | Not reported | Q2 2020 | |
| $436M | 3.79% | 21.93% | Not reported | Q1 2025 | |
| $390M | 3.39% | 20.45% | Not reported | Q3 2021 | |
| $341M | 2.96% | 7.79% | -19.5% | Q1 2021 | |
| $324M | 2.81% | 8.12% | Not reported | Q4 2022 | |
| $287M | 2.49% | 16.72% | New | Q2 2026 | |
| $234M | 2.04% | 15.32% | Not reported | Q4 2024 | |
| BTBCAXBicara Therapeutics Inc. | $215M | 1.87% | 11.01% | Not reported | Q3 2024 |
| $208M | 1.80% | 8.71% | Not reported | Q1 2023 | |
| $205M | 1.78% | 12.31% | -0.5% | Q2 2021 | |
| $179M | 1.56% | 6.39% | Not reported | Q1 2025 | |
| $179M | 1.55% | 23.98% | Not reported | Q1 2026 | |
| $174M | 1.51% | 72.65% | +82.2% | Q3 2024 | |
| $172M | 1.49% | 18.32% | Not reported | Q2 2021 | |
| $160M | 1.39% | 7.24% | Not reported | Q3 2023 | |
| $158M | 1.38% | 6.20% | Not reported | Q3 2013 | |
| $157M | 1.36% | 13.96% | Not reported | Q4 2015 | |
| NNUVLNuvalent, Inc. | $154M | 1.34% | 39.83% | -50.8% | Q2 2024 |
| $151M | 1.31% | 1.44% | New | Q2 2026 | |
| $148M | 1.29% | 2.55% | New | Q2 2026 | |
| $147M | 1.28% | 19.68% | Not reported | Q3 2021 | |
| $120M | 1.04% | 11.45% | +28.9% | Q1 2018 | |
| $109M | 0.95% | 0.51% | +0.6% | Q4 2024 | |
| $87M | 0.76% | 10.92% | Not reported | Q4 2020 | |
| $84.9M | 0.74% | 7.10% | +7.7% | Q4 2013 | |
| $81.6M | 0.71% | 5.78% | Not reported | Q2 2025 | |
| $76.6M | 0.67% | 3.23% | Not reported | Q2 2021 | |
| $71.7M | 0.62% | 7.70% | Not reported | Q3 2025 | |
| $70.6M | 0.61% | 1.12% | New | Q2 2026 | |
| $67.3M | 0.58% | 9.10% | +87.0% | Q4 2015 | |
| $67.2M | 0.58% | 9.15% | Not reported | Q2 2023 | |
| $65.4M | 0.57% | 6.26% | New | Q2 2026 | |
| $62.4M | 0.54% | 3.89% | 0.0% | Q1 2026 | |
| $61.8M | 0.54% | 9.94% | Not reported | Q4 2024 | |
| $56.1M | 0.49% | 29.03% | Not reported | Q3 2021 | |
| $54.8M | 0.48% | 6.67% | -32.9% | Q2 2020 | |
| $49.1M | 0.43% | 9.81% | +2.9% | Q4 2025 | |
| $46.4M | 0.40% | 9.63% | Not reported | Q4 2025 | |
| $44.2M | 0.38% | 4.41% | -55.6% | Q1 2021 | |
| $43.5M | 0.38% | 9.83% | Not reported | Q2 2021 | |
| $42.4M | 0.37% | 2.46% | -12.6% | Q1 2026 | |
| $41M | 0.36% | 3.65% | +1.3% | Q3 2024 | |
| $37.4M | 0.32% | 6.51% | Not reported | Q4 2020 | |
| $37.3M | 0.32% | 0.49% | Not reported | Q1 2026 | |
| $36.3M | 0.32% | 2.59% | Not reported | Q4 2025 | |
| $36.1M | 0.31% | 29.01% | Not reported | Q2 2022 | |
| $34.5M | 0.30% | 8.13% | New | Q2 2026 | |
| Q1 2026Reported May 15, 202685 positions | |||||
| $2.35B | 24.92% | 16.59% | Not reported | Q1 2015 | |
| $667M | 7.07% | 7.95% | +7.0% | Q2 2020 | |
| $580M | 6.14% | 9.74% | Not reported | Q2 2018 | |
| $467M | 4.95% | 20.51% | Not reported | Q3 2021 | |
| $397M | 4.21% | 21.97% | Not reported | Q1 2025 | |
| $328M | 3.48% | 9.70% | Not reported | Q1 2021 | |
| $306M | 3.24% | 8.19% | Not reported | Q4 2022 | |
| NNUVLNuvalent, Inc. | $260M | 2.75% | 80.98% | +34.8% | Q2 2024 |
| $219M | 2.32% | 4.78% | +62.1% | Q1 2024 | |
| $208M | 2.21% | 9.33% | +5.0% | Q1 2023 | |
| $208M | 2.20% | 23.99% | New | Q1 2026 | |
| $196M | 2.07% | 14.03% | +48.2% | Q4 2015 | |
| $168M | 1.78% | 15.58% | Not reported | Q4 2024 | |
| $157M | 1.66% | 6.42% | +24.0% | Q1 2025 | |
| $156M | 1.65% | 18.38% | Not reported | Q2 2021 | |
| $151M | 1.60% | 6.23% | Not reported | Q3 2013 | |
| BTBCAXBicara Therapeutics Inc. | $144M | 1.53% | 11.07% | +4.3% | Q3 2024 |
| $120M | 1.28% | 1.34% | Not reported | Q1 2024 | |
| $108M | 1.14% | 12.38% | Not reported | Q2 2021 | |
| $107M | 1.14% | 0.51% | Not reported | Q4 2024 | |
| $105M | 1.12% | 8.20% | Not reported | Q3 2023 | |
| $96.4M | 1.02% | 9.98% | Not reported | Q1 2021 | |
| $95M | 1.01% | 9.96% | Not reported | Q2 2020 | |
| $87.2M | 0.92% | 10.94% | Not reported | Q4 2020 | |
| $84.9M | 0.90% | 3.70% | New | Q1 2026 | |
| $81.8M | 0.87% | 2.06% | Not reported | Q4 2025 | |
| $80.3M | 0.85% | 9.70% | +1.0% | Q4 2025 | |
| $77.4M | 0.82% | 23.66% | +0.1% | Q3 2021 | |
| $67.2M | 0.71% | 9.49% | +60.7% | Q1 2018 | |
| $63.5M | 0.67% | 39.87% | Not reported | Q3 2024 | |
| $62.1M | 0.66% | 3.98% | New | Q1 2026 | |
| $59.1M | 0.63% | 6.61% | Not reported | Q4 2013 | |
| $54.5M | 0.58% | 7.70% | Not reported | Q3 2025 | |
| $51.6M | 0.55% | 7.44% | Not reported | Q2 2025 | |
| $49.5M | 0.52% | 29.06% | +40.6% | Q3 2021 | |
| $47M | 0.50% | 9.66% | -10.7% | Q2 2023 | |
| $46.4M | 0.49% | 9.09% | Not reported | Q3 2022 | |
| $45.8M | 0.49% | 2.61% | Not reported | Q4 2025 | |
| $40.1M | 0.43% | 9.86% | Not reported | Q2 2021 | |
| $38.8M | 0.41% | 2.98% | Not reported | Q4 2020 | |
| $38.2M | 0.41% | 13.33% | Not reported | Q1 2024 | |
| $36.6M | 0.39% | 9.96% | Not reported | Q4 2024 | |
| $35.5M | 0.38% | 29.03% | Not reported | Q2 2022 | |
| $31.6M | 0.34% | 4.76% | +103.4% | Q1 2021 | |
| $29.4M | 0.31% | 0.52% | New | Q1 2026 | |
| $28.9M | 0.31% | 3.72% | Not reported | Q3 2024 | |
| $28.7M | 0.30% | 6.75% | Not reported | Q1 2024 | |
| $28.3M | 0.30% | 6.42% | Not reported | Q3 2025 | |
| $28M | 0.30% | 9.53% | Not reported | Q4 2025 | |
| $26.9M | 0.28% | 2.81% | New | Q1 2026 | |
| Q4 2025Reported Feb 17, 202671 positions | |||||
| $2.19B | 22.46% | 16.59% | Not reported | Q1 2015 | |
| CTCDTXCidara Therapeutics, Inc. | $743M | 7.62% | 10.70% | Not reported | Q2 2015 |
| $714M | 7.31% | 9.92% | +17.4% | Q2 2018 | |
| ABRNAMAvidity Biosciences, Inc. | $623M | 6.39% | 5.71% | Not reported | Q3 2021 |
| $495M | 5.07% | 8.18% | -10.4% | Q2 2020 | |
| $407M | 4.17% | 22.15% | -5.2% | Q1 2025 | |
| $335M | 3.43% | 8.35% | -5.8% | Q4 2022 | |
| $321M | 3.29% | 22.71% | Not reported | Q3 2021 | |
| $309M | 3.17% | 9.70% | 0.0% | Q4 2015 | |
| $266M | 2.72% | 8.98% | Not reported | Q1 2023 | |
| $259M | 2.65% | 9.82% | Not reported | Q1 2021 | |
| $195M | 2.00% | 15.61% | Not reported | Q4 2024 | |
| NNUVLNuvalent, Inc. | $189M | 1.94% | 60.08% | +50.8% | Q2 2024 |
| $157M | 1.61% | 5.22% | +25.3% | Q1 2025 | |
| $154M | 1.58% | 18.53% | Not reported | Q2 2021 | |
| $131M | 1.34% | 29.13% | Not reported | Q2 2022 | |
| $130M | 1.33% | 8.26% | Not reported | Q3 2023 | |
| $127M | 1.30% | 10.94% | Not reported | Q4 2020 | |
| $123M | 1.26% | 7.43% | Not reported | Q3 2013 | |
| BTBCAXBicara Therapeutics Inc. | $117M | 1.20% | 12.29% | Not reported | Q3 2024 |
| $110M | 1.13% | 1.48% | Not reported | Q1 2024 | |
| $97.5M | 1.00% | 12.38% | Not reported | Q2 2021 | |
| $84.2M | 0.86% | 9.97% | +5.6% | Q2 2020 | |
| AACLXArcellx, Inc. | $82.6M | 0.85% | 2.19% | -58.3% | Q2 2024 |
| $77.7M | 0.80% | 23.64% | -64.1% | Q3 2021 | |
| $70.7M | 0.72% | 13.96% | +172.7% | Q1 2021 | |
| $69.2M | 0.71% | 1.10% | -50.6% | Q3 2025 | |
| $68.5M | 0.70% | 9.09% | -40.8% | Q3 2022 | |
| $66.9M | 0.68% | 13.33% | Not reported | Q1 2024 | |
| $66.4M | 0.68% | 3.73% | -43.8% | Q1 2024 | |
| $65M | 0.67% | 3.20% | Not reported | Q4 2020 | |
| $59.2M | 0.61% | 10.97% | New | Q4 2025 | |
| $56.6M | 0.58% | 7.44% | +245.6% | Q2 2025 | |
| $53.1M | 0.54% | 2.07% | New | Q4 2025 | |
| $49.7M | 0.51% | 6.85% | Not reported | Q1 2024 | |
| $49.2M | 0.50% | 8.73% | +24.3% | Q3 2025 | |
| $43.6M | 0.45% | 9.97% | +30.5% | Q4 2024 | |
| $43.5M | 0.45% | 2.63% | New | Q4 2025 | |
| $42.4M | 0.43% | 9.81% | +23.9% | Q2 2023 | |
| $42.3M | 0.43% | 6.07% | Not reported | Q3 2021 | |
| $42.3M | 0.43% | 40.14% | Not reported | Q3 2024 | |
| $36.7M | 0.38% | 1.06% | New | Q4 2025 | |
| $34.7M | 0.36% | 6.44% | Not reported | Q3 2025 | |
| $32.8M | 0.34% | 7.36% | Not reported | Q1 2018 | |
| $31.5M | 0.32% | 24.65% | Not reported | Q3 2021 | |
| $24.9M | 0.26% | 5.40% | Not reported | Q3 2015 | |
| $24.9M | 0.26% | 9.44% | +2.7% | Q3 2025 | |
| $21.7M | 0.22% | 9.61% | New | Q4 2025 | |
| $20.1M | 0.21% | 26.35% | Not reported | Q4 2022 | |
| $20M | 0.20% | 15.20% | Not reported | Q3 2020 | |
| Q3 2025Reported Nov 14, 202567 positions | |||||
| $2.04B | 25.19% | 16.94% | Not reported | Q1 2015 | |
| $574M | 7.07% | 8.52% | +2.2% | Q2 2018 | |
| $431M | 5.31% | 9.20% | Not reported | Q2 2020 | |
| ABRNAMAvidity Biosciences, Inc. | $376M | 4.64% | 5.89% | +18.9% | Q3 2021 |
| CTCDTXCidara Therapeutics, Inc. | $322M | 3.97% | 11.47% | Not reported | Q2 2015 |
| $307M | 3.79% | 23.49% | Not reported | Q1 2025 | |
| 8ETNB89bio, Inc. | $292M | 3.60% | 13.41% | Not reported | Q4 2019 |
| $288M | 3.55% | 8.96% | Not reported | Q4 2022 | |
| $278M | 3.42% | 9.27% | +19.1% | Q1 2023 | |
| $273M | 3.37% | 18.61% | Not reported | Q2 2021 | |
| AACLXArcellx, Inc. | $249M | 3.07% | 5.26% | Not reported | Q2 2024 |
| $195M | 2.40% | 14.62% | Not reported | Q1 2024 | |
| $171M | 2.10% | 22.88% | Not reported | Q3 2021 | |
| $169M | 2.08% | 9.86% | +5.3% | Q1 2021 | |
| $133M | 1.64% | 11.36% | Not reported | Q4 2015 | |
| $132M | 1.62% | 15.67% | Not reported | Q4 2024 | |
| $113M | 1.39% | 6.69% | Not reported | Q1 2024 | |
| BTBCAXBicara Therapeutics Inc. | $110M | 1.35% | 12.74% | Not reported | Q3 2024 |
| $110M | 1.35% | 14.75% | Not reported | Q2 2021 | |
| $109M | 1.34% | 10.99% | Not reported | Q4 2020 | |
| NNUVLNuvalent, Inc. | $108M | 1.33% | 39.83% | Not reported | Q2 2024 |
| $104M | 1.28% | 4.51% | Not reported | Q1 2025 | |
| $96.6M | 1.19% | 21.96% | 0.0% | Q1 2021 | |
| $94.1M | 1.16% | 18.90% | Not reported | Q3 2022 | |
| $92.7M | 1.14% | 61.17% | +87.7% | Q2 2022 | |
| $82.7M | 1.02% | 9.46% | Not reported | Q2 2020 | |
| $77M | 0.95% | 8.60% | Not reported | Q3 2023 | |
| $64.8M | 0.80% | 2.75% | New | Q3 2025 | |
| $63.2M | 0.78% | 46.08% | Not reported | Q3 2021 | |
| $43.5M | 0.54% | 1.18% | +2.7% | Q4 2024 | |
| $42.5M | 0.52% | 0.83% | Not reported | Q4 2023 | |
| $41.8M | 0.51% | 7.67% | Not reported | Q4 2024 | |
| $39.7M | 0.49% | 9.76% | Not reported | Q2 2023 | |
| $35.9M | 0.44% | 7.46% | 0.0% | Q1 2018 | |
| MMTSRMetsera, Inc. | $35.4M | 0.44% | 0.64% | Not reported | Q1 2025 |
| $28.3M | 0.35% | 40.34% | Not reported | Q3 2024 | |
| $28.1M | 0.35% | 7.02% | New | Q3 2025 | |
| $27.5M | 0.34% | 1.29% | Not reported | Q4 2020 | |
| $26.1M | 0.32% | 6.45% | New | Q3 2025 | |
| $25.5M | 0.31% | 24.65% | Not reported | Q3 2021 | |
| $24.9M | 0.31% | 7.57% | New | Q3 2025 | |
| $22.4M | 0.28% | 15.21% | Not reported | Q3 2020 | |
| $19.5M | 0.24% | 7.06% | Not reported | Q2 2020 | |
| $18.8M | 0.23% | 7.98% | Not reported | Q3 2021 | |
| $16.8M | 0.21% | 1.79% | Not reported | Q3 2021 | |
| $16.6M | 0.20% | 1.66% | New | Q3 2025 | |
| $15.5M | 0.19% | 1.06% | Not reported | Q1 2025 | |
| $15.1M | 0.19% | 26.44% | Not reported | Q4 2022 | |
| $13.2M | 0.16% | 14.13% | Not reported | Q2 2021 | |
| $11.7M | 0.14% | 0.32% | Not reported | Q1 2020 | |
Premium opens every quarter this fund has filed